Vol. 2 No. 10 (2022)
Health Technology Reviews

Intravenous Iron Isomaltoside for Patients With Iron Deficiency Undergoing Elective Surgery

Published October 27, 2022

Key Messages

  • The results of 1 randomized controlled trial did not find a difference in functional status (6-minute walk distance and New York Heart Association class), hand grip strength, or health-related quality of life for patients who underwent a transcatheter aortic valve implantation treated with iron isomaltoside versus placebo.
  • There was 1 (1.4%) hypersensitivity reaction and 1 (1.4%) episode of chest pain in patients treated with iron isomaltoside in the randomized controlled trial. Rates of other adverse events were similar between patients treated with iron isomaltoside and placebo.